Oral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment

Background Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population‐level data. Methods Patients aged und...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2021-11, Vol.68 (11), p.e29204-n/a, Article 29204
Hauptverfasser: Fraser, Jess, Wills, Lorna, Fardus‐Reid, Fahmina, Irvine, Lucy, Elliss‐Brookes, Lucy, Fern, Lorna, Cameron, Alison L., Pritchard‐Jones, Kathy, Feltbower, Richard G., Shelton, Jon, Stiller, Charles, McCabe, Martin G.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population‐level data. Methods Patients aged under 25 years at cancer diagnosis (1995–2017) with a treatment record of single‐agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012–2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy. Results Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables. Conclusions This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29204